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Rosiglitazone (RGZ), a thiazolidinedione ligand of the peroxisome proliferator-activated receptor (PPAR)-γ,h a sb e e nr e c e n t l y
described as possessing antitumoral properties. We investigated RGZ eﬀect on cell proliferation in two cell line models (SW13
and H295R) of human adrenocortical carcinoma (ACC) and its interaction with the signaling pathways of the activated IGF-I
receptor (IGF-IR). We demonstrate a high expression of IGF-IR in the two cell lines and in ACC. Cell proliferation is stimulated
by IGF-I in a dose- and time-dependent manner and is inhibited by RGZ. The analysis of the main intracellular signaling
pathwaysdownstreamoftheactivatedIGF-IR,phosphatidylinositol3-kinase(PI3K)-Akt,andextracellularsignal-regulatedkinase
(ERK1/2) cascades reveals that RGZ rapidly interferes with the Akt and ERK1/2 phosphorylation/activation which mediates IGF-I
stimulated proliferation. In conclusion, our results suggest that RGZ exerts an inhibitory eﬀect on human ACC cell proliferation
by interfering with the PI3K/Akt and ERK1/2 signaling pathways downstream of the activated IGF-IR.
Copyright © 2008 Giulia Cantini et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Adrenocorticalcarcinoma(ACC) is a rare tumor with an
incidence of approximately 1-2 per million population per
year.ACCisaveryaggressivetumor,characterizedbyapoor-
prognosis: approximately 50% of patients do not survive
beyond 2 years from the diagnosis and the 5-year mortality
rateisbetween20%and60%[1].Itspoorprognosisdepends
mainly upon the limited therapeutic resources. At present,
a complete surgical removal following an early diagnosis is
the only valuable option for the tumor’s cure. Moreover,
other than improved surgical management, the prognosis
for ACC has not changed signiﬁcantly over the past three
decades [2]. The tumor is, in fact, resistant to radio- and
chemotherapy and medical treatment very rarely leads to a
complete remission in the case of recurrences or metastatic
spread. Although several new medical therapeutic options
have been recently proposed [3], at present the medical
treatment of advanced ACC is far from being satisfactory,
due to our poor knowledge of the molecular mechanisms
leading to malignant transformation of adrenocortical cells.
In fact, although some intracellular signaling pathways have
been shown to be altered in ACC cells [4], eﬀorts to identify
the events leading to neoplastic transformation and tumor
invasiveness have met with limited success. The role of IGF-I
system in mediating proliferation and progression has been
welldocumentedinseveralcancers,includingadrenocortical
carcinoma [5]. In particular, ACC, as well as the H295R cell
line [6] ,o v e r e x p r e s sb o t hI G F - I I[ 7] and its promiscuous
receptor IGF-IR [8] in comparison to adrenal adenomas and
normal adrenal tissue. The overexpressed IGF-II is thought
to act in a paracrine fashion through the IGF-IR to sustain
tumor and cell proliferation [6, 9, 10].
Peroxisome proliferator activated receptor (PPAR)-γ is
a ligand-activated transcriptor factor and a member of the
nuclear hormone receptors superfamily. Thiazolidinediones2 PPAR Research
(TZDs), which are a family of PPAR-γ ligands, have been
introduced in the therapy of type 2 diabetes mellitus (T2D)
because of their ability to reduce insulin resistance. In
the last few years, an increasing amount of experimental
data showing the ability of these drugs to exert additional
pleiotropic actions such as regulation of inﬂammatory
processes and of cancer cell growth has been published [11].
TZD eﬀects seem to be mainly due to their ability to bind
and activate PPARγ diﬀerentially expressed in adipose and
other tissues. Upon ligand binding, PPARγ heterodimerizes
with the 9-cis retinoic acid receptor (RXR) on speciﬁc
responsive elements in the promoters of genes involved
in glucose and insulin homeostasis, lipid metabolism, and
cellular diﬀerentiation. Besides this transactivating activity,
a ligand-dependent transcriptional transrepression mecha-
nism involving PPARγ/RXR complex has been described.
According to such a model, the heterodimerized receptor
represses gene transcription in a DNA-binding independent
way by physically sequestering activated transcriptional fac-
tors or their coactivators [12]. More recently, an increasing
number of TZD eﬀects, and in particular the antineoplastic
ones, have been shown to be independent of PPARγ activity
[13]. Finally, rapid nongenomic activities of TZDs, not
resulting in modulation of gene transcription but aﬀecting
posttranslational modiﬁcations involved in cell signaling,
have been reported [14].
In addition to their action as insulin sensitizers, TZDs
inhibit cell growth in breast, colon, prostate, lung, pancreas,
stomach, thyroid, liver and adrenal cancers [15]. However,
themolecularmechanismsunderlyingsuchpharmacological
activities remain to be elucidated.
Rosiglitazone (RGZ) and pioglitazone (PGZ), the two
most widely used PPARγ agonists, have been shown to
inhibit growth and invasiveness of the human adrenal cancer
cell line H295R [16]a sw e l la st oi n d u c ec e l ld i ﬀerentiation
and apoptosis [10]. Moreover, H295R cells and both normal
and tumoral adrenal tissue express PPARγ,w i t hn od i ﬀer-
ences in the level of expression between tumoral and normal
tissue and no correlation with clinical parameters such as
tumor size, hormonal proﬁle, and so forth [10, 16].
In this study, we investigate two diﬀerent cell models of
ACC,namely,SW13andH295Rlines,whethertheTZDRGZ
may exert its antiproliferative action on human ACC cell
lines by interfering with the intracellular pathways activated
by IGF-IR.
2. MATERIALS AND METHODS
2.1. Reagents
Anti-phospho [Akt (Ser473), ERK1/2 (T202/Y204)] and
anti-Akt antibodies were from Cell Signaling Technology,
Inc. (Danvers, Mass, USA). Anti-ERK1/2, anti-IGF-IRβ,a n d
anti-actin antibodies were from Santa Cruz Biotechnology,
Inc. (Santa Cruz, Calif, USA). Anti-PI3K p85 regulatory
subunit antibody was from Upstate Biotechnology (Lake
Placid, NY, USA). Rosiglitazone was from Alexis Biochem-
icals (San Diego, Calif, USA). MTS solution was purchased
from Promega (Madison, Wis, USA). IGF-I was from
SigmaAldrich(SanLouis,Mo,USA).[Methyl-3H]thymidine
([3H]TdR) was purchased from NEN Life Science Products
(Boston,Mass,USA).NVP-AEW541wasprovidedbyNovar-
tis (Basel, Switzerland).
2.2. Tissuespecimensandcellcultures
A total of three normal human adrenal glands, three adrenal
carcinomas, and three adenomas were used in this study.
Normal adrenal glands were removed during an expanded
nephrectomy due to renal carcinoma or from organ donors
(age 32–72 years). Approval for the use of human material
was given by the Local Ethical Committee. Informed consent
was obtained from each patient. Adrenocortical fragments,
collected immediately after surgery, were snap frozen in
liquid nitrogen and stored at −80◦C.
The human ACC cell lines H295R and SW13 were
obtained from the American Type Culture Collection
(Manassas, Va, USA). SW13 were cultured in DMEM/F-12
medium (Sigma-Aldrich) with 10% FBS (Euroclone), 2mM
L-glutamine, 100U/ml penicillin, and 100μg/ml strepto-
mycin. H295R need DMEM/F-12 medium enriched with
a mixture of insulin/transferrin/selenium (Sigma-Aldrich).
Cells were incubated at 37◦C in a humidiﬁed 5% CO2
atmosphere.
Subconﬂuent cells starved 24 hours were treated with
diﬀerent stimuli added to serum-free medium. Rosiglitazone
was added simultaneously with IGF-I, at the doses and for
the time intervals (15 minutes for western blot analysis and
from 24 hours up to 7 days for proliferation experiments)
indicated in ﬁgure legends.
Cells were pretreated 1 hour with NVP-AEW541 before
addition of other stimuli. For incubations longer than 24
hours, media and stimuli were replaced every day.
2.3. MTSassay
SW13 and H295R were seeded in 96-well plates at the
density of 3·103 and 8·103 cells/well, respectively. After
24-hour starvation in serum-free (SF) medium, cells were
treated with the diﬀerent stimuli in SF medium for the
indicated times (see ﬁgure legends) and cell number in each
well was evaluated by MTS assay (Promega), according to
the manufacturer’s instructions. The samples were analyzed
by an ELISA plate reader (Wallac 1420 - PerkinElmer) at
490 nm wavelength to measure optical density (OD). Each
experimentalpointwasperformedinquintuplicateinatleast
three independent experiments.
2.4. Cellproliferationassays
2.4.1. Viablecellcounting
Cells were seeded in 12-well plates (1,8·104 and 5·104
cells/well for SW13 and H295R, resp.), and after 24-hour
starvation were treated for 2 or 4 days in SF medium,
then trypsinizedand counted in the haemocytometer. Mean
cell number was obtained by counting triplicate in threeGiulia Cantini et al. 3
diﬀerent experiments. Dead cells were excluded by trypan
blue exclusion test.
2.4.2. DNAsynthesisassay:[3H]thymidineuptake
DNA synthesis was evaluated according to the amount
of [3H]TdR incorporated into trichloroacetic acid (TCA)-
precipitated materials. Cells seeded at diﬀerent density
(5·104 or2,5·104 H295Rcells/wellin12or24wellplates,and
1,8·104 SW13 cells/well in 12 well plates) were grown in 10%
FBS complete medium till 70% conﬂuence. After 24-hour
starvation, cells were treated with IGF-I or RGZ in 1% FBS
mediumfortheindicatedtimes(1–7days)pulsingthemwith
1.0μCi/ml [3H]TdR (6.7Ci/mmol) 4 hours before stopping
proliferation in ice-cold 10% TCA. After washing in TCA
and then in methanol, cells were solubilized in 0.2N NaOH,
and radioactivity was measured in the scintillation counter.
Experiments were performed in triplicate and repeated at
least three times.
2.5. Westernblotanalysis
Treated cells were extracted in lysis buﬀer (20mM Tris,
pH 7.4, 150mM NaCl, 0.5% Triton X-100, 1mM Na3VO4,
1mM PMSF). Thirty μg of proteins measured by Coomassie
reagent (BIO-RAD Labs, Hercules, Calif, USA) were loaded
onto 8–10% reducing SDS-PAGE. After separation, pro-
teins transferred to nitrocellulose membranes were 1 hour
blocked at room temperature in 5% skimmed milk in
TTBS (0.1% Tween-20, 20mM Tris, 150mM NaCl) and
incubated overnight with primary antibodies at appropriate
dilutions followed by peroxidase-secondary IgG (1:3000).
Proteins were revealed by BM-enhanced chemiluminescence
system (Roche Diagnostics, Milan, Italy). Image acquisition
anddensitometric analysis were performed with Quantity
One software on a ChemiDoc XRS instrument (BIO-RAD
Labs, Hercules, Calif, USA). All western blots were repeated
inatleast3independentexperiments.Membranere-probing
was performed after stripping procedure (Pierce, Rockford,
Il, USA).
PI3kinaseassay
T r e a t e dc e l l sw e r ee x t r a c t e di nl y s i sb u ﬀer A (20mM Tris, pH
7.4, 137mM NaCl, 1mM CaCl2,1m MM g C l 2, 1% NP-40,
1mMN a 3VO4, 1mM PMSF). After protein measurement,
aliquots containing equal amount of proteins (300μg) were
precleared with 50μl of Protein G-Sepharose. Precleared
lysates were then immunoprecipitated overnight at 4◦Cw i t h
3μg of rabbit anti-p85 PI3K antibody in the presence of 50μl
of Protein A-Sepharose. Sepharose beads washed in a 10mM
Tris-HCl (pH 7.4) containing 0.1mM EGTA and 5mM LiCl,
weresuspendedinakinasebuﬀer(10mMTris-HCl,150mM
NaCl, 5mM EDTA) containing 20μgo fL - α-phosphatidyl
inositol (Sigma-Aldrich, St. Louis, Mo, USA), 25mM MgCl2
and 10μCi of [γ32P]ATP and incubated for 20 minutes at
room temperature. The reaction was stopped by the addition
of 60μl of 6M HCl + 160μl of chloroform:methanol (1:1).
Lipids were then resolved by thin layer chromatography
plates (TLC silica gel 60) (Merck Laborchimica, Florence,
Italy) in chloroform, methanol, water and ammonium
hydroxide (60:47:11, 3:2). Dried TLC sheets were developed
by autoradiography. Band quantiﬁcation was performed
with ChemiDoc XRS instrument (BIO-RAD Labs, Hercules,
Calif, USA).
2.6. Statisticalanalysis
Results are expressed as mean ± SE. The eﬀect of diﬀerent
concentrations of IGF-I and RGZ on cell proliferation was
tested by One-Way ANOVA. Multiple Post Hoc comparisons
were performed by Bonferroni’s correction. Student’s τ-test
for paired or unpaired data was applied when appropriate
for comparison of two sets of data. P<. 05 was taken as
signiﬁcant.
3. RESULTS
Adrenal cancer is characterized by an increased expression
of the IGF-IR compared to both nontumoral and adenomal
adrenal tissues as demonstrated by western blot analysis
with a speciﬁc antibody against the β subunit of IGF-IR
(Figure 1(a)). A marked expression of this receptor isalsop-
resent in SW13 and in particular in H295R adrenocortical
cancer cells (Figure 1(a)), suggesting that both tissue and cell
systems may be highly responsive to the eﬀects of IGF-I and
IGF-II.
In order to study the role of IGF-IR and of its down-
stream intracellular signaling pathways on cell proliferation,
we stimulated both SW13 and H295R cells with increasing
concentrations of the receptor’s elective ligand, IGF-I. IGF-
I is able to induce cell proliferation in a time- and dose-
dependent manner as demonstrated by evaluating cell via-
bility through MTS assay in both SW13 (Figure 1(b))a n d
H295R(Figure 1(c))cellsstimulatedwithincreasingconcen-
trations ofIGF-I (1to 50nM)for24 hours upto 7 days.Such
a stimulatory eﬀect is conﬁrmed by [3H]thymidine uptake
experiments in H295R cells (Figure 1(d)).
Following 24-hour treatment, RGZ reduces cell via-
bility in a dose-dependent manner in SW13 cells treated
(Figure 2(b))o rn o t( Figure 2(a)) with 10nM IGF-I, show-
ing an IC50 of 22.48 ± 1.54μM( c o e ﬃcient of variation
6.9%) as calculated with ALLFIT program [17], Figure 2(c).
Interestingly, the IC50s derived fromthe two RGZ dose
response viability curves obtained for IGF-I-treated and
untreated cells are not statistically diﬀerent, suggesting that
the eﬀect of RGZ is similar independently of exogenous
IGF-I stimulation. Thus, we chose to use 20μMR G Zi n
all the experiments. The inhibitory eﬀect of RGZ on cell
proliferation in basal conditions is signiﬁcantly increased
with the time of incubation as evaluated by [3H]thymidine
uptake experiments in both SW13 (Figure 2(d)) and H295R
(Figure 2(e)) cells. Again, thenegativeeﬀect on cell viability
exerted by RGZ is similar in IGF-I treated and untreated
SW13 cells (Figures 3(a)–3(e)). Conversely, in H295R cells
where the eﬀect of RGZ requires longer times to become
evident,RGZisalsoabletorevertIGF-I-stimulation(Figures
3(f)–3(h)). Both IGF-I-stimulated proliferation and the4 PPAR Research
Mw
(kDa)
171
109
40
A
D
E
A
C
C
N
O
R
H
2
9
5
R
S
W
1
3
IGF-IRβ
(97kDa)
Actin
(42kDa)
(a)
12 347
Time (days)
0
0.2
0.4
0.6
0.8
1
O
D
(
4
9
0
n
m
)
n = 6 SW13
§§
◦ ## ∗ # #
§ # #
◦
#
#
(b)
12347
Time (days)
0
0.05
0.1
0.15
0.2
0.25
O
D
(
4
9
0
n
m
)
n = 6 H295R
§ # #
# §
# #
§
# #
∗
##
(c)
1 234
Time (days)
1500
2000
2500
3000
3500
4000
4500
5000
5500
6000
10000
12000
14000
16000
[
3
H
]
t
h
y
m
i
d
i
n
e
u
p
t
a
k
e
(
C
P
M
) n = 6
∗ ∗
∗
∗
Ctrl
IGF-I 1nM
IGF-I 10nM
IGF-I 50nM
(d)
Figure 1: Adrenocortical cancer is responsive to IGFs. (a) Western blot analysis of adrenocortical tissues (adrenocortical carcinoma: ACC;
normal adrenal tissue: NOR; adrenocortical adenoma: ADE) and adrenocortical cancer cell lines (SW13 and H295R) reveals a high
expression of IGF-IR in cancer tissue and cells and lower levels in normal and adenoma tissues. Western blot for actin was performed
for lane protein normalization. Molecular weight (Mw) markers are indicated. The eﬀects of cell incubation with increasing doses of IGF-
I (1, 10 and 50nM) for the indicated times on cell proliferation were evaluated by MTS in SW13 (b) and H295R (c) and conﬁrmed in
H295R by evaluation of [3H]TdR incorporation in cell DNA content (d). Data represent mean ± SE OD (b), (c) or mean ± SE of [3H]TdR
incorporation (counts per minute, cpm) (d). Statistical signiﬁcance versus respective control: ∗P<. 05, ◦P<. 01, §P<. 005, #P<. 001.
inhibitoryeﬀectofRGZareconﬁrmedbySW13(Figure 3(i))
and H295R (Figure 3(j)) cell counting at 2- and 4-day
incubation, respectively.
To elucidate the intracellular mechanism by which RGZ
aﬀects adrenal cancer cell proliferation, we investigated the
eﬀects of the drug on the two main intracellular signaling
pathways engaged by the activated IGF-IR, namely, the
phosphatidyl inositol 3 kinase (PI3K)-Akt cascade and the
extracellular signal-regulated (ERK) signaling [18].
Rapidstimulation(15minutes)ofSW13(Figure 4(a))and
H295R (Figure 4(b)) cells with 10nM IGF-I determines
an increased phosphorylation of Akt in Ser473, resulting
in the activation of the enzyme (Figure 4,u p p e ra n d
lower panels). Concomitant addition of 20μMR G Zf o r
15 minutes in the presence or absence of IGF-I interferes
with Akt phosphorylation/activation in SW13 (Figure 4(a))
and H295R (Figure 4(b)) cells. The inhibitory eﬀect of
RGZ is statistically signiﬁcant versus IGF-I only, but this
trend is also present on active Akt in basal conditions
(Figure 4 lower panels). The in vitro immunokinase assay
f o rP I 3 Kp e r f o r m e do nS W 1 3( Figure 5(a)) and on H295R
(Figure 5(b)) lysates demonstrates a rapid activation (15
minutes) of the enzyme by IGF-I, which is reverted by
co-incubation with RGZ. The inhibitory eﬀect of RGZ is
evident in basal conditions in H295R cells only (Figures
5(a), 5(b)). Similarly, RGZ interferes with IGF-I-rapid stim-
ulation of phosphorylation/activation of ERK1/2 in SW13
(Figure 6(a)) and H295R (Figure 6(b)), but, conversely, the
eﬀectofRGZinbasalconditionsisevidentinSW13cellsonly
(Figures 6(a), 6(b)).
In order to further demonstrate the involvement of Akt
and ERK signaling downstream of the IGF-IR in medi-
ating cell proliferation, we use the NVP-AEW541 (NVP)
inhibitor of the IGF-IR tyrosine kinase activity. As shown
in Figure 7(a), NVP is able to block phosphorylation of Akt
(upper panel) and ERK1/2 (middle panel) both in the basal
conditions and following 15-minute IGF-I stimulation. The
block of the IGF-IR system by NVP results in inhibition
of IGF-I-stimulated cell proliferation evaluated at 2 and
4 days of treatment in SW13 (Figure 7(b)) and H295R,
respectively, (Figure 7(c)). Moreover, a further addition of
RGZ to the inhibitor results in no signiﬁcant reduction ofGiulia Cantini et al. 5
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Figure 2: Dose dependent eﬀects of RGZ on adrenocortical carcinoma cell proliferation. The dose dependent eﬀect of RGZ on SW13 cell
proliferation was evaluated by MTS assay at 48-hour stimulation in the absence (a), (c) or presence (b) of 10nM IGF-I. A complete dose
response curve for RGZ (10−3 to 2·102 μM) on cell proliferation in SW13 is reported (c), showing the IC50 for RGZ calculated by ALLFIT
program [17]. Data represent mean ± SE percentage of OD over controls (RGZ 0μM). Statistical signiﬁcance versus respective control (RGZ
0μM): ∗P<0.05, #P<0.001. The time dependent eﬀect of RGZ administration (20μM) on cell proliferation was evaluated at the indicated
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Figure 5: RGZ inhibits IGF-I stimulated PI3K. PI3K activity in SW13 (a) and H295R (b) treated or not for 15 minutes with 10nM IGF-I and
20μM RGZ was evaluated by an in vitro assay after immunoprecipitation with an antibody against the PI3K regulatory subunit p85. The
spots correspond to PI3K catalytic product [32P]phosphatidyl inositol phosphate (PIP). Representative of two similar experiments. Mean ±
SE (n = 2) of phospho-Akt band intensity (arbitrary units) is shown in the table under each blot.
cell proliferation in the presence of IGF-I compared to NVP
+ IGF-I (Figures 7(b), 7(c)) suggesting that RGZ growth
inhibition is mediated via IGF-IR signaling.
Finally, we investigated whether RGZ could aﬀect not
only the downstream signaling of IGF-IR, but also the levels
ofthe receptoritself. Figure 8showsthattheIGF-IR levelsdo
not change following up to 4-day stimulation of SW13 (a) d
H295R (b) cells with 20μM RGZ.
4. DISCUSSION
Although adrenocortical carcinomas are very rare tumors,
they are very aggressive and highly resistant to chemo- and
radiotherapy. Moreover, the use of the adrenolytic agent,
mitotane (o,p-DDD), is the only medical therapy available
at present. Thus, a better knowledge of the molecular
mechanisms underlying the tumor growth and progression
is mandatory in order to develop more selective and speciﬁc
treatments.
Recently,PPARγ ligandshavebeendescribedassuppress-
ing tumor cell proliferation as well as inducing apoptosis
and a more diﬀerentiated phenotype in several types of
cancers [15], including adrenocortical carcinoma [10, 16],
thus suggesting the use of these drugs as a potential new
anticancer therapy. However, all these studies have been
performed either in vivo, on animal models, or in vitro, on8 PPAR Research
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Figure 6:RGZdampensIGF-IstimulatedERK1/2phosphorylation.WesternblotanalysisofSW13(a)andH295R(b)celllysatesfollowing15-
minutes stimulation with 10nM IGF-I and 20μM RGZ, reveals an increased phosphorylation of ERK1/2 following IGF-I, which is reverted
by RGZ. Lane protein normalization for ERK1/2 is shown in the middle panels. Molecular weight markers are indicated. Mean ± SE of
phospho-ERK1/2 band intensity over respective Ctrl is shown in 3 independent experiments for SW13 (a) and H295R (b) cells (lower
panels). ∗P<0.05 versus respective Ctrl; ◦P<. 05 and #P<. 005 versus IGF-I.
human cancer cells. Moreover, these anticancer eﬀects have
been observed with concentrations of PPARγ agonists which
are not only higher than the clinical doses used for T2D
treatment but also aﬀect PPAR α and δ isoforms, being no
longer selective for PPARγ.H o w e v e r ,t r e a t m e n tw i t hR G Z
doses higher than the therapeutical 8mg/die has been well
tolerated and did not result in any increase in the percentage
ofadverseeventscomparedtotheplacebogroupinadouble-
blind clinical trial [19].
At present, only three papers address the eﬀects of
PPARγ ligands in ACC using H295R cells as an in vitro
model [10, 16, 20]. Both RGZ and pioglitazone (PIO),
the most used PPARγ TZD ligands, inhibit cell growth by
aﬀecting key cell cycle elements and inducing apoptosis
[10, 16], also dampening cell invasiveness through reduction
of metalloproteinase 2 (MMP2) expression and activity [16].
Moreover, in these cells, RGZ and PIO induce a more
diﬀerentiated phenotype where steroidogenesis is increased
due to a signiﬁcant upregulation of MC2-R and Star
expression [10].
In this paper, we use two diﬀerent cell models of ACC,
H295R, and SW13. H295R cells retain the ability to synthe-
size steroid hormones, while SW13, derived from a stage IV
tumor, do not, thus suggesting them to be less diﬀerentiated
than H295R. Both cell lines seem to be suitable models for
studying the eﬀects of RGZ on IGF-I/IGF-IR axis, since they
express high levels of the IGF-IR, similarly to ACC tissue.
In order to stimulate IGF-IR and its downstream signaling
cascade,weadded tothe cellsincreasing concentrationsof its
elective ligand, IGF-I. Indeed, IGF-IR binds IGF-I with a 15-
fold higher aﬃnity than IGF-II [21]. However, H295R cells
havebeendescribedasproducinghighlevelsofIGF-II,which
acts in an autocrine-paracrine loop stimulating the IGF-IR
axis even in basal conditions [8]. For this reason, in our
experimental procedure, we changed cell incubation media
every day to remove the endogenously produced IGF-II thus
making the receptor more responsive to the exogenously
added IGF-I.
In this condition, IGF-I was able to stimulate cell pro-
liferation in a dose- and a time-dependent manner in both
cell models through activation of the two main downstream
intracellular signaling cascades involving phosphatidyl inos-
itol 3-kinase (PI3K)-Akt and extracellular signal-regulated
kinase (ERK1/2) [21], as described also for other tumors
[18]. However, these two pathways are already active even in
basal conditions, as demonstrated by the rather high levels
of ERK and Akt phosphorylation as well as of PI3K activity
found in the absence of IGF-I stimulation, probably due to
the paracrine-autocrine eﬀects of endogenously produced
IGF-II [8].
RGZ has been demonstrated to impair IGF-I systemboth
in vivo and in vitro by reducing IGF-I production in boneGiulia Cantini et al. 9
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Figure 7: ERK and Akt activation downstream of the IGF-IR
mediates IGF-I stimulation of cell proliferation. Western blot analysis
of H295R cell lysates following 15-minute stimulation with 10nM
IGF-I in the presence or absence of 1μM NVP-AEW541 (NVP)
inhibitor of the tyrosine kinase activity of IGF-IR (a). The inhibitor
blocks phosphorylation of Akt (upper panel) and of ERK1/2
(middle panel) both in basal conditions and following IGF-I
stimulation. Lane protein normalization for actin is shown in
the lower panel. Molecular weight markers are indicated. Cell
proliferation was evaluated by MTS assay following 2 or 4 day
stimulation with the indicated treatments (10nM IGF-I, 20μM
RGZ,1μMNVP)inSW13(b)orH295R(c)cells,respectively.Mean
±SEpercentageofODoverrespectivecontrolIGF-Itakenas100%.
#P<. 001 versus IGF-I, n = 6.
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Figure 8: R G Zd o e sn o ta ﬀect IGF-IR levels. Western blot analysis of
SW13 (a) and H295R (b) cell lysates following 2, 3, and 4 day cell
incubation in the absence (Ctrl) or in the presence of 20μMR G Z
revealsnosigniﬁcantchangeinIGF-IR(upperpanels).Laneprotein
normalization for actin is shown in the lower panels. Molecular
weight markers are indicated. Representative of two independent
experiments.
marrow cells and in the liver [22]. Moreover, troglitazone
inhibits IGF-I tumor-promoting activity in mouse skin by
aﬀecting the intracellular pathway involving AMP kinase
[23].
In SW13 as well as in H295R cells, RGZ was able to
signiﬁcantly reduce cell proliferation in a dose- and time-
dependent manner as evaluated by diﬀerent techniques
(MTS,thymidineuptakeandcellcounting),withacalculated
IC50 of 22.48 ± 1.54μM. This concentration is higher
than the RGZ plasma levels estimated from the total area
under the plasma concentration-time curve (Cmax 1.33μM)
obtained by pharmacokinetic studies on subjects undergoing
oral RGZ administration with the therapeutical dosage of
8mg/die [24]. However, it is in perfect agreement with the
doses currently used for in vitro studies, in particular in
cancer cells [10, 16]. Although the RGZ inhibitory eﬀect on
cell proliferation and viability has already been reported in
H295R cells [10, 16], this is the ﬁrst time that RGZ IC50
and maximal eﬀect have been calculated with an appropriate
statistical analysis [17], thus validating the current dose
of 20μM used in cancer studies and suggesting that the
anti-proliferative eﬀects of RGZ are obtained at higher
concentrations than the ones eﬀective on insulin sensitivity
[13]. Toxic studies associated with a pharmacokinetic studies
to deﬁne the RGZ oral dose capable of resulting in a
range of 20μM circulating concentration of RGZ and to10 PPAR Research
investigate the possible toxic eﬀect associated to such doses,
are mandatory in order to hypothesize a possible therapeutic
use of RGZ and other TZD for ACC treatment.
In addition to its eﬀect on cell proliferation in basal
conditions, RGZ was also eﬀective on cell growth induced by
addition of increasing concentrations of IGF-I. Interestingly,
such an inhibitory eﬀect was similar in the presence or in
the absence of IGF-I only in SW13 cells, while in H295R,
RGZ also prevents the stimulatory eﬀect of IGF-I. However,
the inhibitory eﬀect of RGZ was reached more slowly in
H295R (4–7 days) than in SW13 (1-2 days), probably due
to the diﬀerences in the kinetic of duplication between
the two cell lines. Moreover, in H295R RGZ inhibition
increases with the dose of IGF-I, while in SW13, the eﬀect
was similar independently of the dose of the growth factor.
Consequently, the IC50 calculated for RGZ curve on SW13
cell proliferation was similar in the presence or absence of
IGF-I.
In order to elucidate at which level RGZ interferes with
the activated IGF-I axis both in basal conditions (IGF-IR
activated by endogenously produced IGF-II) and following
a further activation of the receptor by exogenous addition
of IGF-I, we investigated the signaling pathways acting
downstream of the receptor. RGZ was able to block the rapid
activation of the PI3K-Akt axis induced by IGF-I. In agree-
ment with the experiments on cell proliferation, we found
that in H295R cells only, RGZ was more eﬀective on IGF-I-
treated than on untreated cells. RGZ also aﬀected the ERK
pathway through inhibition of the rapid phosphorylation-
activationofERK1and2isoforms.AsimilareﬀectofRGZon
rapid phosphorylation of ERKs has been recently described
in the inﬂammatory response of endothelial cells [14]. Such
an eﬀect is too rapid (15 minutes) to be ascribed to the
classical transactivation mechanism of PPARγ on speciﬁc
target genes, and suggests a PPARγ independent mechanism
or a nongenomic activity of the receptor. Interestingly,
among the anticancer action exerted by RGZ in H295R,
both PPARγ dependent and independent eﬀects seem to
coexist in these cells, since the PPARγ antagonist GW9662
has been demonstrated to block RGZ induction of MC2R
expression and cortisol secretion but not RGZ inhibition
of cell proliferation (Betz et al., 2005). Further studies are
requiredtoelucidatetheprecisemechanismbywhichPPARγ
ligands aﬀect rapid signaling in these cells. Interestingly, no
eﬀect of RGZ was detected up to 4 day stimulationon the
level of IGF-IR in both cell lines. In accordance, Betz and
colleagues described that IGF-II production increased with
time despite the clear growth-suppressive eﬀects of RGZ and
PIOinH295R[10].OurﬁndingssuggestthatRGZinhibition
acts on the signaling pathways downstream but not at the
level of the IGF-IR.
In conclusion, our result shed new light on the molecular
mechanisms underlying cell proliferation and progression
in adrenal carcinoma, contributing to demonstrate that the
inhibitory eﬀect exerted by RGZ on cell growth is due to
the TDZ interferences with the two main signaling pathways
downstream of the activated IGF-IR. RGZ ability to block
the IGF-IR axis suggests the potential application of this
molecule for the treatment of ACC.
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